Tc-99m MDP and Tc-99m MIBI in the assessment of spondyloarthritis presenting as bone metastasis before treatment with infliximab.
Hadi
Ali
A
Departments of Rheumatology and Nuclear Medicine, Derriford Hospital, Plymouth, United Kingdom.
Al-Nahhas
Adil
A
Vivian
Gillian
G
Hickling
Peter
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000000981:diagnostic imaging* / Q000188:drug therapy; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013122:Spinal Diseases / Q000000981:diagnostic imaging* / Q000188:drug therapy; D013669:Technetium Tc 99m Medronate; D017256:Technetium Tc 99m Sestamibi
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D000069285:Infliximab; D013669:Technetium Tc 99m Medronate